The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2022 | The use of tafasitamab in DLBCL
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses the use of the anti-CD19 monoclonal antibody tafasitamab for the treatment of diffuse large B-cell lymphoma (DLBCL). Tafasitamab has shown remarkable results in combination with lenalidomide in relapsed/refractory (R/R) DLBCL and will likely become a new standard of care (SOC), especially for patients who are not transplant-eligible. It is currently unknown whether tafasitamab is better or worse than chimeric antigen receptor T-cell (CAR-T) therapy but recent studies suggest it compares well with other treatments for DLBCL. It is also necessary to investigate whether tafasitamab should be used prior to CAR-T therapy and further define its place in the treatment regimen. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
